OBJECTIVES The aim of this study was to determine whether transcatheter aortic valve replacement (TAVR) with the mechanically expanded Lotus valve (Boston Scientific, Natick Massachusetts) offers potential benefits over treatment with the self-expanding CoreValve (Medtronic, Minneapolis, Minnesota).
The CoreValve Revalving System (Medtronic) is a self-expanding device fashioned from nitinol wire.
The distinctive frame has a flared inflow portion to anchor in the native annulus, a constrained midsegment to avoid coronary obstruction, and a flared outflow portion to improve coaxial alignment to the aortic flow plane. In a U.S. pivotal trial, the CoreValve was found to have a significantly higher survival rate at 1 year than surgical valve replacement in a highrisk cohort (10) . These results mirror favorable safety and efficacy data from large single-center (11, 12) , national (13) (14) (15) , and multinational (16) registries.
The Lotus device (Boston Scientific, Natick, Massachusetts) is a new TAVR device that uses a unique mechanical expansion mechanism. It is made of a single braided nitinol wire and 3 bovine pericardial leaflets. The outer surface of the lower half of the frame is covered with an adaptive seal, essentially a polymer membrane that concertinas as the device is expanded and, in doing so, occupies any small residual interstices, sealing the frame against the native aortoventricular interface (8, 17) . This has been reported to reduce the rate of paraprosthetic aortic regurgitation (PAR). The device is fully repositionable and resheathable, even in the completely expanded position, allowing for fine control and the potential for removal should the device position or size be deemed suboptimal. The Lotus device was studied in the REPRISE I (Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LotusÔ Valve System) (18) PRE-PROCEDURAL TTE ASSESSMENT. TTE was performed using an iE33 machine (Philips, Best, the Netherlands) before enrollment. All scans were assessed by an experienced echocardiologist with severity of aortic stenosis graded based on European
Association of Echocardiography and American Society of Echocardiography joint guidelines (21) . An independent echocardiography core laboratory subsequently reviewed these studies with these results used for study analysis.
PRE-PROCEDURAL INVASIVE ANGIOGRAPHIC
ASSESSMENT. All patients underwent invasive coronary and peripheral angiography to confirm access site suitability and to identify significant coronary artery disease warranting treatment before TAVR.
Treatment of concomitant coronary artery disease was at the discretion of the implanting cardiologist.
Right heart catheterization was performed to exclude significant primary pulmonary hypertension and corroborate ultrasound-based hemodynamic measurements.
TREATMENT. All TAVR procedures were performed in the cardiac catheterization laboratory with patients under general anesthesia or conscious sedation. Deployment of the respective devices was performed in strict accordance with manufacturer's guidelines and current best practices (8, 16, 17) . Table 3 . 
All-cause death was 0% in the Lotus cohort and 4%
in the CoreValve cohort at 7 days. At 7 days, 1 death in the CoreValve cohort was due to ischemic colitis after a partially deployed prosthesis was retrieved through the aorta, whereas the other death was due to progressive congestive cardiac failure in the setting of severe PAR that was refractory to post-dilation.
There was 1 additional death in the Lotus cohort at 30 days due to a hemorrhagic stroke, and 1 additional death in the CoreValve cohort due to pneumonia and respiratory failure. The percentage of patients with mild AR was similar to that at discharge: 14.3% and 66% (p < 0.001), respectively ( Table 5) . Gooley et al.
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other core laboratory-adjudicated trials (10, 16) . The rate of post-dilation in the CoreValve cohort (26%)
was also comparable to the rate reported in the CoreValve United States Investigational Device Exemption trial (20.3%) (10) . Importantly, the apparent difference in device success in the current study was not reflected in differences in mortality nor clinical efficacy to 30 days.
Significant PAR after TAVR deployment has been shown to correlate with increased morbidity and mortality (32, 33) . Factors contributing to regurgitation include baseline annular eccentricity (34), the depth of device implantation (35) , and the degree of prosthesis oversizing (36) , whereas the degree of calcification has been an inconsistent predictor in various studies (37) (38) (39) . In this study, the native basal WHAT IS NEXT?The clinical significance of these differences will need to be tested in a larger randomized trial such as the currently recruiting REPRISE III study.
